Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Therapeutics and Clinical Risk Management
|
March 10, 2022
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
Jeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of Comparative Effectiveness Research
|
August 16, 2023
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
Jeffrey Frankel, David Staskin, Susann Varano, et al.
European Urology
|
August 6, 2014
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials
Christopher Chapple, Vik Khullar, Victor W Nitti, et al.
American Journal of Cancer Research
|
February 10, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies
Rushikesh Potdar, Benjamin A Gartrell, Robert Given, et al.
International Journal of Clinical Practice
|
June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Advances in Therapy
|
December 18, 2021
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
Jeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of Comparative Effectiveness Research
|
December 3, 2025
Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder
Holly E Richter, Benjamin Chastek, Adam Carrera, et al.
Journal of Clinical Pharmacology
|
April 13, 2018
Cardiovascular Safety of the β<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial
William B White, Christopher Chapple, Christian Gratzke, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Therapeutics and Clinical Risk Management
|
March 10, 2022
An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
Jeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of Comparative Effectiveness Research
|
August 16, 2023
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
Jeffrey Frankel, David Staskin, Susann Varano, et al.
European Urology
|
August 6, 2014
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials
Christopher Chapple, Vik Khullar, Victor W Nitti, et al.
American Journal of Cancer Research
|
February 10, 2022
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies
Rushikesh Potdar, Benjamin A Gartrell, Robert Given, et al.
International Journal of Clinical Practice
|
June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
David Staskin, Jeffrey Frankel, Susann Varano, et al.
Advances in Therapy
|
December 18, 2021
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
Jeffrey Frankel, David Staskin, Susann Varano, et al.
Journal of Comparative Effectiveness Research
|
December 3, 2025
Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder
Holly E Richter, Benjamin Chastek, Adam Carrera, et al.
Journal of Clinical Pharmacology
|
April 13, 2018
Cardiovascular Safety of the β<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial
William B White, Christopher Chapple, Christian Gratzke, et al.
Page
of 2